Prednisone Dosing for Acute Lymphoblastic Leukemia Induction Therapy
For induction therapy in acute lymphoblastic leukemia, prednisone should be dosed at 40-60 mg/m²/day for 28 days, administered in the morning prior to 9 am. 1, 2
Standard Induction Dosing
The established prednisone dose for ALL induction is 40 mg/m²/day for 4 weeks (28 days), as demonstrated in multiple validated regimens 1:
Linker 4-drug regimen: Uses prednisone at standard dosing as part of vincristine, daunorubicin, prednisone, and asparaginase combination, achieving 93% complete remission rates 1
MRC UKALL XII/ECOG E2993 protocol: Employs prednisone during the 4-week phase I induction with vincristine, daunorubicin, and L-asparaginase, resulting in 5-year overall survival of 41% for Ph-negative ALL 1
Pediatric protocols: Consistently use 40 mg/m²/day dosing, which has been adapted for adolescent and young adult populations with proven efficacy 3, 4
Administration Guidelines
Timing is critical for optimal efficacy and reduced toxicity 2:
- Administer in the morning prior to 9 am to align with maximal adrenal cortex activity (2 am to 8 am) 2
- This timing minimizes adrenocortical suppression 2
- Give with food or milk to reduce gastric irritation 2
- When using large doses, administer antacids between meals to prevent peptic ulcers 2
Critical Safety Considerations
Adrenal suppression is a major concern requiring vigilant monitoring 5:
- Approximately 46% of children develop adrenal suppression 2 weeks after completing 28 days of prednisone 5
- Suppression can persist for up to 20 weeks in some patients 5
- Children ≥5 years experience significantly longer suppression than younger children 5
- Patients with adrenal suppression cannot mount adequate stress responses during febrile neutropenia 5
Never abruptly discontinue prednisone 2:
- Taper gradually after induction to prevent withdrawal syndrome 2
- Drug-induced secondary adrenocortical insufficiency may persist up to 12 months after large doses 2
- During any stressful situation within this period, hormone therapy should be reinstituted 2
- Salt and/or mineralocorticoid supplementation may be necessary 2
Dexamethasone Alternative
Dexamethasone (6 mg/m²/day) is superior to prednisone for reducing CNS relapse 3:
- 6-year isolated CNS relapse rate: 3.7% with dexamethasone vs 7.1% with prednisone (p=0.01) 3
- 6-year event-free survival: 85% with dexamethasone vs 77% with prednisone (p=0.002) 3
- However, dexamethasone causes more profound and prolonged adrenal suppression 5
Monitoring Requirements
Close surveillance is mandatory throughout and after induction 2:
- Monitor for signs of infection, as patients are immunosuppressed and may have impaired stress responses 5
- Assess for hyperglycemia, hypertension, and fluid retention 2
- Consider bone protection strategies if treatment duration ≥3 months is anticipated, including calcium, vitamin D, and bisphosphonates 2
- Monitor intraocular pressure if therapy continues beyond 6 weeks 2
Common Pitfalls to Avoid
- Do not use afternoon or evening dosing, which increases HPA axis suppression 2
- Do not assume normal adrenal function immediately post-induction—testing may be warranted before stressful procedures 5
- Do not overlook osteoporosis prevention in patients receiving prolonged therapy 2
- Do not stop steroids abruptly even if the patient appears clinically well 2